{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2001"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2008391"],"location":["United States"],"study_start_month":["10"],"keyword":["Irinotecan","Capecitabine"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer","description":"This study will assess the efficacy and safety of intermittent oral Xeloda administration in combination with irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals.","dates":{"creation":"2001-10-15"},"accession":"2008391","cross_references":{"ClinicalTrials___gov":["NCT00048139"]}}